LAB Stock Overview
Develops, manufactures, sells, and markets animal and human health medicine products in Spain, rest of European Union, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Labiana Health, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.14 |
| 52 Week High | €3.18 |
| 52 Week Low | €1.09 |
| Beta | -0.31 |
| 11 Month Change | -13.71% |
| 3 Month Change | -30.97% |
| 1 Year Change | 67.19% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -53.48% |
Recent News & Updates
Labiana Health (BME:LAB) Has No Shortage Of Debt
Nov 18
Is Labiana Health (BME:LAB) Weighed On By Its Debt Load?
Jun 08Shareholder Returns
| LAB | ES Pharmaceuticals | ES Market | |
|---|---|---|---|
| 7D | 15.1% | -3.5% | 0.5% |
| 1Y | 67.2% | 11.7% | 16.6% |
Return vs Industry: LAB exceeded the Spanish Pharmaceuticals industry which returned 11.9% over the past year.
Return vs Market: LAB exceeded the Spanish Market which returned 17% over the past year.
Price Volatility
| LAB volatility | |
|---|---|
| LAB Average Weekly Movement | 7.1% |
| Pharmaceuticals Industry Average Movement | 4.1% |
| Market Average Movement | 2.9% |
| 10% most volatile stocks in ES Market | 5.4% |
| 10% least volatile stocks in ES Market | 0.6% |
Stable Share Price: LAB's share price has been volatile over the past 3 months compared to the Spanish market.
Volatility Over Time: LAB's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Spanish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1958 | 364 | Manuel Ortega | www.labiana.com |
Labiana Health, S.A. develops, manufactures, sells, and markets animal and human health medicine products in Spain, rest of European Union, and internationally. The company offers anesthetics-sedative, anti-infective, anti-inflammatory, antiparasitic, hormonal, and nutritional products; metabolism regulators; and vitamin products. It also provides sterile, lyophilized, and biological formats; and Fosfomycin trometamol under the Fosfomicina Labiana brand name.
Labiana Health, S.A. Fundamentals Summary
| LAB fundamental statistics | |
|---|---|
| Market cap | €15.07m |
| Earnings (TTM) | -€1.18m |
| Revenue (TTM) | €66.14m |
0.2x
P/S Ratio-12.8x
P/E RatioIs LAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LAB income statement (TTM) | |
|---|---|
| Revenue | €66.14m |
| Cost of Revenue | €28.10m |
| Gross Profit | €38.03m |
| Other Expenses | €39.21m |
| Earnings | -€1.18m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.17 |
| Gross Margin | 57.51% |
| Net Profit Margin | -1.78% |
| Debt/Equity Ratio | 885.5% |
How did LAB perform over the long term?
See historical performance and comparison